INOVIO PHARMACEUTICALS, INC.
For the period ended Dec 31, 2024. Filed Mar 18, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 18, 2025
INO$1.45-4.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
| For the Year ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Net loss | $(107,254,126) | $(135,117,352) |
| Other comprehensive loss: | ||
| Foreign currency translation | 32,403 | (3,920) |
| Unrealized (loss) gain on short-term investments, net of tax | (45,469) | 40,060 |
| Comprehensive loss | $(107,267,192) | $(135,081,212) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.